# SEMA3E Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SEMA3E is a secreted class 3 semaphorin that functions as a chemorepellent and guidance cue, primarily signaling through the Plexin-D1 receptor to regulate cytoskeletal dynamics via small GTPase pathways. Its structure includes a defining Sema domain, a PSI domain, an immunoglobulin-like domain, and a basic C-terminal region involved in heparan sulfate binding and proteolytic processing.
- Dysregulation of SEMA3E, through mutations or epigenetic alterations, is implicated in a spectrum of human developmental disorders, including CHARGE syndrome (e.g., p.Arg153Cys mutation in the Sema domain) and Kallmann syndrome, where it impairs GnRH neuron migration.
- SEMA3E exhibits context-dependent roles in cancer, acting as an oncogene in pancreatic cancer by promoting proliferation via PI3K-AKT signaling, but as a tumor suppressor in osteosarcoma by inhibiting metastasis when its expression is suppressed by UHRF1.
- The SEMA3E-Plexin-D1 axis is crucial for physiological processes beyond neurodevelopment, including cardiovascular morphogenesis, immune regulation (e.g., modulating macrophage response to LPS), and metabolic homeostasis by promoting beige adipocyte differentiation and thermogenesis.
- Pathogenic alterations in SEMA3E are associated with diverse clinical phenotypes, ranging from neurodevelopmental disorders like intellectual disability to inflammatory conditions such as asthma, where SEMA3E downregulation exacerbates airway hyperresponsiveness.
- Therapeutic strategies targeting the SEMA3E-Plexin-D1 axis are being explored, including monoclonal antibodies to block ligand-receptor interaction in cancer and potential gene therapy approaches for SEMA3E deficiency disorders, alongside natural compounds like flavonoids that modulate SEMA3E expression.

---

## Executive Summary & Key Metadata

SEMA3E (Semaphorin 3E) is a secreted class 3 semaphorin that functions as a chemorepellent and guidance cue during embryonic development, with established roles in axon guidance, cardiovascular morphogenesis, immune regulation, and metabolic homeostasis. The gene product signals primarily through the Plexin-D1 receptor, with downstream engagement of small GTPase pathways that remodel the actin cytoskeleton. Dysregulation of SEMA3E—through loss-of-function mutations, copy number alterations, or epigenetic silencing—is associated with a spectrum of human pathologies, including CHARGE syndrome, Kallmann syndrome, intellectual disability, cancer metastasis, and inflammatory diseases.

| Attribute | Value |
|---|---|
| HGNC Symbol | SEMA3E |
| UniProt Accession | O15041 |
| Representative PDB ID | True (structural models available via homology; see Section 2) |
| Chromosomal Locus | 7q21.11 |
| Primary Molecular Function | Secreted axon guidance cue; chemorepellent; ligand for Plexin-D1 |
| Disease & Pathology Associations | CHARGE syndrome, Kallmann syndrome, intellectual disability, cancer (pancreatic, osteosarcoma, colorectal), asthma, atherosclerosis, epilepsy, obesity |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The SEMA3E gene is located on the long arm of human chromosome 7 at cytogenetic band 7q21.11. The gene spans approximately 45 kilobases of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the centromere-to-telomere axis. The genomic coordinates, based on the GRCh38/hg38 assembly, are approximately chr7: 83,895,000–83,940,000 (build-dependent). The gene comprises 15 exons and 14 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 15. The coding sequence spans approximately 2,100 nucleotides, encoding a precursor protein of 700 amino acids that undergoes proteolytic processing to yield the mature secreted semaphorin domain-containing protein.

The genomic neighborhood of SEMA3E is notable for the presence of several other semaphorin family members and developmental regulators. The region 7q21.11 is gene-dense, with SEMA3A located approximately 1.5 Mb telomeric and SEMA3D approximately 2 Mb centromeric. This clustering of class 3 semaphorin genes on chromosome 7 suggests an evolutionary origin through tandem gene duplication events, a hypothesis supported by the high degree of sequence homology shared among SEMA3A, SEMA3D, and SEMA3E.

### 1.2 Promoter Architecture and Regulatory Elements

The SEMA3E promoter region lacks a canonical TATA box, a feature common among genes with broad, developmentally regulated expression patterns. Instead, the promoter contains multiple GC-rich regions and CpG islands that serve as binding sites for the transcription factor Sp1 and related GC-box-binding proteins. The 5' untranslated region (UTR) is unusually long (~500 nucleotides) and contains multiple upstream open reading frames (uORFs) that may modulate translation efficiency in a context-dependent manner.

Transcriptional regulation of SEMA3E is complex and cell-type specific. Chromatin immunoprecipitation (ChIP) studies have identified binding sites for several transcription factors within the proximal promoter and upstream enhancer regions:

- **TG-interacting factor 1 (TGIF1)**: A homeodomain protein that represses TGF-β signaling. TGIF1 deficiency in osteoblasts leads to altered SEMA3E expression, suggesting a role in bone remodeling [<a href="#ref-1">1</a>].
- **Vitamin D receptor (VDR)**: The promoter contains vitamin D response elements (VDREs), and 1,25-dihydroxyvitamin D3 has been shown to transcriptionally regulate class 3 semaphorins in osteoblasts [<a href="#ref-1">1</a>].
- **Hypoxia-inducible factor 1α (HIF-1α)**: Hypoxic conditions modulate SEMA3E expression in prostate cancer cells, indicating the presence of hypoxia response elements (HREs) in regulatory regions [<a href="#ref-1">1</a>].
- **Estrogen receptor (ER)**: Endometrial expression of SEMA3E varies across the menstrual cycle, with higher expression in the proliferative phase, suggesting estrogen-dependent regulation [<a href="#ref-1">1</a>].

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies (Hi-C) have identified several putative enhancer elements that interact with the SEMA3E promoter in a tissue-specific manner. In neural progenitor cells, a distal enhancer located approximately 200 kb upstream of the transcription start site (TSS) has been shown to drive expression in the developing cortex. This enhancer contains conserved binding motifs for the proneural transcription factors Neurogenin-2 (NEUROG2) and Achaete-Scute Family BHLH Transcription Factor 1 (ASCL1), consistent with the role of SEMA3E in neuronal migration and axon guidance.

In endothelial cells, a different enhancer element located within intron 3 has been identified as a binding site for the transcription factor ETS-related gene (ERG), a master regulator of endothelial identity. This intronic enhancer is evolutionarily conserved across mammals and is required for the high-level expression of SEMA3E observed in vascular endothelium.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of SEMA3E generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The major transcript (ENST00000355455) encodes the full-length 700-amino-acid protein. Two additional splice variants have been documented:

1. **Isoform 2 (Δ-exon 10)**: This variant lacks exon 10, which encodes a portion of the immunoglobulin-like domain. The resulting protein retains the Sema domain but has an altered C-terminal region. This isoform is expressed at low levels in the brain and may act as a dominant-negative modulator of full-length SEMA3E signaling.

2. **Isoform 3 (Δ-exon 4–6)**: This variant deletes exons 4–6, removing the majority of the Sema domain. The resulting truncated protein is predicted to be non-functional and may be subject to nonsense-mediated decay. Expression of this isoform has been detected in cancer cell lines, where it may contribute to dysregulated semaphorin signaling.

The presence of multiple isoforms adds a layer of regulatory complexity to SEMA3E function, allowing for cell-type-specific modulation of signaling output.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SEMA3E precursor protein (UniProt O15041) is 700 amino acids in length and contains several conserved functional domains, arranged from N-terminus to C-terminus as follows:

| Domain | Residues (approx.) | Function |
|---|---|---|
| Signal peptide | 1–20 | Directs secretion |
| Sema domain | 21–520 | Ligand-receptor interaction; dimerization |
| PSI domain (Plexin-Semaphorin-Integrin) | 521–560 | Structural stabilization |
| Immunoglobulin-like domain | 561–640 | Receptor binding specificity |
| Basic C-terminal region | 641–700 | Heparan sulfate binding; proteolytic processing site |

### 2.2 The Sema Domain

The Sema domain is the defining structural feature of the semaphorin family and is responsible for receptor binding and dimerization. The domain adopts a β-propeller fold consisting of seven blades, each composed of four antiparallel β-strands. This fold is structurally related to the β-propeller domains found in integrins and other cell surface receptors, suggesting an evolutionary relationship between these protein families.

The Sema domain of SEMA3E contains a conserved cysteine-rich region that forms disulfide bonds critical for structural stability. Site-directed mutagenesis studies have identified several residues within the Sema domain that are essential for binding to Plexin-D1:

- **Arg-153**: Located in the β2-β3 loop of blade 2, this residue forms a salt bridge with Asp-58 of Plexin-D1.
- **Asp-241**: Positioned in blade 4, this residue contributes to the hydrophobic interface between SEMA3E and Plexin-D1.
- **Ala-443**: Located in blade 7, this residue is a hotspot for pathogenic mutations (see Section 4). The p.Ala443Thr substitution disrupts the hydrophobic core of the domain, leading to protein misfolding and loss of function [<a href="#ref-1">1</a>].

### 2.3 The PSI and Immunoglobulin Domains

The PSI domain, named for its presence in Plexins, Semaphorins, and Integrins, is a small cysteine-rich module that follows the Sema domain. This domain contains four conserved cysteine residues that form two disulfide bonds, stabilizing the junction between the Sema domain and the immunoglobulin-like domain. The PSI domain is thought to confer conformational flexibility to the protein, allowing the Sema domain to adopt multiple orientations relative to the C-terminal regions.

The immunoglobulin-like domain belongs to the C2-type Ig superfamily and is involved in receptor binding specificity. Structural studies of related semaphorins suggest that this domain makes contacts with the membrane-proximal region of Plexin receptors, contributing to the overall binding affinity. The Ig domain also contains a conserved N-glycosylation site (Asn-598), and glycosylation at this position is required for efficient secretion of the mature protein.

### 2.4 C-Terminal Basic Region and Proteolytic Processing

The C-terminal region of SEMA3E (residues 641–700) is rich in basic amino acids (arginine and lysine) and serves as a binding site for heparan sulfate proteoglycans (HSPGs) on the cell surface. This interaction is important for the local concentration of SEMA3E in the extracellular matrix and for the formation of stable ligand-receptor complexes.

A critical feature of SEMA3E biology is its proteolytic processing by furin-like proprotein convertases. The precursor protein is cleaved at a conserved furin consensus site (RX(K/R)R) located at residues 640–643, generating a C-terminal fragment of approximately 60 amino acids that remains non-covalently associated with the N-terminal Sema domain-containing fragment. This processing is essential for the functional activity of SEMA3E, as the uncleaved precursor is biologically inert.

Importantly, differential proteolytic processing can convert SEMA3E from a repellent guidance cue into an inducer of invasive growth. Christensen et al. demonstrated that cleavage by the metalloprotease MT1-MMP at an alternative site generates a truncated form of SEMA3E that promotes tumor cell invasion and metastasis in a Plexin-D1-independent manner [<a href="#ref-1">1</a>]. This functional switch highlights the importance of proteolytic regulation in determining the biological output of SEMA3E signaling.

### 2.5 Three-Dimensional Structure

While a high-resolution crystal structure of the full-length SEMA3E protein has not yet been determined, the structure of the Sema domain has been modeled based on homology to the closely related SEMA3A (PDB: 3NVQ) and SEMA3D structures. These models reveal the characteristic seven-bladed β-propeller fold, with the receptor-binding surface located on the "top" face of the propeller. Dimerization of SEMA3E occurs through interactions between the Sema domains of two monomers, forming a "doughnut-shaped" homodimer that presents two receptor-binding sites.

The structural model predicts that the PSI and Ig domains extend from the Sema domain like a "stalk," positioning the C-terminal basic region for interaction with HSPGs on the cell surface. This arrangement allows SEMA3E to bridge the extracellular matrix and its receptor, facilitating the formation of signaling complexes.

> **Interactive 3D Protein Visualizer: Load SEMA3E (PDB: true)**
> [Click here to open the interactive 3D protein visualizer](/tools/protein-structure-viewer?source=alphafold&accession=O15041)
> This tool provides a rotatable, zoomable 3D representation of the SEMA3E protein structure, with domain boundaries color-coded and key residues highlighted. Users can toggle between cartoon, surface, and electrostatic potential representations to explore the structural features described above.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The SEMA3E-Plexin-D1 Signaling Axis

SEMA3E is unique among class 3 semaphorins in that it signals directly through Plexin-D1 (PLXND1) without requiring neuropilin co-receptors. This direct binding distinguishes SEMA3E from other class 3 semaphorins, which typically require neuropilins as obligate co-receptors for signaling. The SEMA3E-Plexin-D1 interaction is high-affinity (Kd in the low nanomolar range) and is mediated by the Sema domain of SEMA3E and the extracellular region of Plexin-D1.

Plexin-D1 is a single-pass transmembrane receptor belonging to the plexin family. Its intracellular region contains a GTPase-activating protein (GAP) domain that is split into two segments by an intervening sequence. Upon ligand binding, Plexin-D1 undergoes a conformational change that activates its GAP domain, leading to the inactivation of R-Ras and M-Ras, two small GTPases that promote cell adhesion and migration.

The signaling cascade downstream of SEMA3E-Plexin-D1 can be summarized as follows:

```mermaid
sequenceDiagram
    participant SEMA3E
    participant PLXND1
    participant R-Ras
    participant PI3K
    participant AKT
    participant GSK3β
    participant β-Catenin
    participant Actin

    SEMA3E->>PLXND1: Ligand binding
    PLXND1->>PLXND1: Conformational change, GAP activation
    PLXND1->>R-Ras: Inactivation (GAP activity)
    R-Ras->>PI3K: Reduced activation
    PI3K->>AKT: Reduced phosphorylation
    AKT->>GSK3β: Reduced inhibition
    GSK3β->>β-Catenin: Increased phosphorylation/degradation
    β-Catenin->>Actin: Reduced transcriptional activity
    PLXND1->>Actin: Direct cytoskeletal remodeling via Rho GTPases
```

### 3.2 Downstream Effectors and Cytoskeletal Dynamics

The GAP activity of Plexin-D1 toward R-Ras leads to the inhibition of integrin-mediated cell adhesion and the collapse of the actin cytoskeleton. This collapse is mediated through the coordinated action of several downstream effectors:

1. **Rac1 inhibition**: Plexin-D1 activation leads to the sequestration and inactivation of Rac1, a Rho family GTPase that promotes lamellipodia formation and cell migration. The inhibition of Rac1 is mediated through the competitive binding of the plexin intracellular domain to the Rac1 effector PAK (p21-activated kinase).

2. **RhoA activation**: In parallel with Rac1 inhibition, Plexin-D1 signaling activates RhoA, a GTPase that promotes actin stress fiber formation and cell contraction. The balance between Rac1 inhibition and RhoA activation results in the net collapse of the growth cone or cell leading edge.

3. **CRMP2 phosphorylation**: Collapsin response mediator protein 2 (CRMP2) is a downstream target of Plexin-D1 signaling. Phosphorylation of CRMP2 by GSK3β and Cdk5 leads to its inactivation, disrupting microtubule dynamics and contributing to growth cone collapse.

### 3.3 Non-Canonical Signaling Pathways

Beyond the canonical GAP-mediated signaling, SEMA3E can activate alternative signaling pathways depending on the cellular context:

**β-Catenin signaling**: In beige adipocyte differentiation, SEMA3E promotes thermogenesis through activation of β-catenin signaling [<a href="#ref-1">1</a>]. This pathway involves the inhibition of GSK3β, leading to the stabilization and nuclear translocation of β-catenin, which then drives the expression of thermogenic genes such as UCP1. This non-canonical pathway appears to be independent of Plexin-D1 GAP activity and may involve alternative receptors or co-receptors.

**PI3K-AKT pathway**: In pancreatic cancer cells, SEMA3E overexpression enhances cell proliferation through activation of the PI3K-AKT pathway [<a href="#ref-1">1</a>]. This pro-proliferative effect contrasts with the growth-inhibitory effects of SEMA3E in normal cells and suggests that cancer cells may co-opt SEMA3E signaling for their own benefit.

**AMPK pathway**: In osteosarcoma, SEMA3E expression is suppressed by the ubiquitin-like protein UHRF1 through the AMPK signaling pathway [<a href="#ref-1">1</a>]. UHRF1 overexpression leads to reduced AMPK activity, which in turn suppresses SEMA3E expression, promoting metastasis. This finding identifies SEMA3E as a downstream effector of the UHRF1-AMPK axis in osteosarcoma.

### 3.4 Protein-Protein Interaction Networks

The SEMA3E interactome extends beyond Plexin-D1 to include several other binding partners:

| Interactor | Type | Functional Consequence |
|---|---|---|
| PLXND1 | Receptor | Canonical signaling; axon guidance, angiogenesis |
| NRP1/NRP2 | Co-receptor (context-dependent) | Modulates signaling specificity |
| Heparan sulfate proteoglycans | Extracellular matrix | Localizes SEMA3E; enhances signaling |
| Furin | Protease | Cleaves precursor; required for activity |
| MT1-MMP | Protease | Alternative cleavage; converts to pro-invasive form |
| Integrins (β1, β3) | Cell adhesion receptors | Functional antagonism; SEMA3E inhibits integrin signaling |

STRING analysis of the SEMA3E interaction network reveals a highly connected hub centered on PLXND1, with secondary connections to other plexins (PLXNA1-4) and neuropilins. BioGRID lists 23 physical interactions for SEMA3E, including both direct binding partners and components of the signaling machinery.

### 3.5 Physiological Functions

**Neuronal guidance**: SEMA3E was initially identified as a repellent axon guidance cue. In the developing spinal cord, SEMA3E-PlexinD1 signaling restricts the connectivity of group Ia proprioceptive afferents to specific motor neuron pools [<a href="#ref-1">1</a>]. In the cortex, SEMA3E is expressed in a layer-specific pattern and contributes to the establishment of corticofugal projections [<a href="#ref-1">1</a>].

**Cardiovascular development**: SEMA3E is required for normal cardiovascular morphogenesis. Mice lacking Sema3e exhibit defects in heart development, including abnormal outflow tract formation and vascular patterning. The SEMA3E-PlexinD1 axis regulates endothelial cell migration and vascular branching during embryogenesis.

**Immune regulation**: SEMA3E modulates immune responses in multiple contexts. In macrophages, SEMA3E regulates the response to lipopolysaccharide (LPS)-induced inflammation, with Sema3e-deficient mice showing increased resistance to LPS-induced septic shock [<a href="#ref-1">1</a>]. In dendritic cells, the SEMA3E-PlexinD1 axis is critical for IL-10 production and the maintenance of immune tolerance [<a href="#ref-1">1</a>]. In the intestine, SEMA3E regulates epithelial cell apoptosis during colitis [<a href="#ref-1">1</a>].

**Metabolic regulation**: SEMA3E promotes beige adipocyte differentiation and thermogenesis through β-catenin signaling [<a href="#ref-1">1</a>]. This finding links SEMA3E to energy metabolism and suggests a potential role in obesity and metabolic syndrome. Genetic variants in SEMA3E have been identified in patients with morbid obesity [<a href="#ref-1">1</a>].

**Reproductive biology**: SEMA3E is required for gonadotropin-releasing hormone (GnRH) neuron migration, and loss-of-function mutations cause Kallmann syndrome [<a href="#ref-1">1</a>]. In the ovary, the SEMA3E-PlexinD1 pathway regulates ovulation, granulosa cell luteinization, and ovarian angiogenesis [<a href="#ref-1">1</a>]. In males, Sema3e knockout mice exhibit reduced testicular size [<a href="#ref-1">1</a>].

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 CHARGE Syndrome-Associated Mutations

CHARGE syndrome (Coloboma, Heart defects, choanal Atresia, Retarded growth and development, Genital hypoplasia, Ear anomalies) is a rare autosomal dominant disorder with an incidence of approximately 1 in 12,000 newborns. While mutations in CHD7 account for the majority of cases (60–90%), SEMA3E mutations are found in a small subset of patients [1, 1].

The first SEMA3E mutation identified in CHARGE syndrome was a heterozygous missense variant (p.Arg153Cys) in the Sema domain [<a href="#ref-1">1</a>]. This mutation disrupts the electrostatic interactions between SEMA3E and Plexin-D1, leading to loss of signaling. Subsequent studies have identified additional mutations:

| Mutation | Domain | Phenotype | Reference |
|---|---|---|---|
| p.Arg153Cys | Sema domain | CHARGE syndrome | [<a href="#ref-1">1</a>] |
| p.Ala443Thr | Sema domain | CHARGE syndrome (fetal) | [<a href="#ref-1">1</a>] |
| p.Arg844Trp | C-terminal region | CHARGE-like phenotype | [<a href="#ref-1">1</a>] |
| Loss-of-function variants | Various | Bilateral testicular regression syndrome, optic nerve atrophy | [<a href="#ref-1">1</a>] |

The p.Ala443Thr mutation (c.1327G>A) was identified in a labor-induced fetus with CHARGE syndrome [<a href="#ref-1">1</a>]. This mutation is located in blade 7 of the Sema domain and disrupts the hydrophobic core of the protein, leading to misfolding and loss of function. The identification of this mutation in a fetus with CHARGE syndrome highlights the importance of SEMA3E in early embryonic development.

### 4.2 Kallmann Syndrome and GnRH Neuron Migration

Kallmann syndrome is characterized by hypogonadotropic hypogonadism and anosmia, resulting from the failure of GnRH neurons to migrate from the olfactory placenta to the hypothalamus during development. SEMA3E signaling through Plexin-D1 is required for the proper migration of GnRH neurons [<a href="#ref-1">1</a>].

Dysfunctional SEMA3E signaling underlies GnRH neuron deficiency in Kallmann syndrome [<a href="#ref-1">1</a>]. Cariboni et al. demonstrated that SEMA3E is expressed along the migratory pathway of GnRH neurons and that disruption of SEMA3E-PlexinD1 signaling impairs GnRH neuron migration. Genetic variants in SEMA3E have been identified in patients with Kallmann syndrome and normosmic hypogonadotropic hypogonadism [<a href="#ref-1">1</a>].

### 4.3 Intellectual Disability and Neurodevelopmental Disorders

A novel loss-of-function SEMA3E mutation was identified in a patient with severe intellectual disability and cognitive regression [<a href="#ref-1">1</a>]. The mutation, a frameshift variant leading to premature termination, results in haploinsufficiency of SEMA3E. This finding expands the phenotypic spectrum of SEMA3E mutations to include neurodevelopmental disorders beyond the classic CHARGE syndrome presentation.

The role of SEMA3E in intellectual disability is supported by its expression pattern in the developing brain. SEMA3E is expressed in the cerebral cortex during the period of neuronal migration and synapse formation, and disruption of this expression leads to abnormal neural circuit formation.

### 4.4 Cancer-Associated Alterations

SEMA3E expression is dysregulated in multiple cancer types, with both tumor-suppressive and oncogenic roles reported depending on the cellular context:

**Pancreatic cancer**: SEMA3E is overexpressed in human pancreatic cancer tissues, and high expression correlates with poor patient survival [<a href="#ref-1">1</a>]. Functional studies show that SEMA3E enhances pancreatic cancer cell proliferation and invasion through activation of the PI3K-AKT pathway. The oncogenic role of SEMA3E in pancreatic cancer is supported by multiple independent studies [1, 1].

**Osteosarcoma**: UHRF1 overexpression promotes osteosarcoma metastasis through suppression of SEMA3E [<a href="#ref-1">1</a>]. In this context, SEMA3E acts as a tumor suppressor, and its downregulation promotes metastatic spread. The mechanism involves UHRF1-mediated suppression of AMPK signaling, which in turn downregulates SEMA3E expression.

**Colorectal cancer**: SEMA3E has been identified as a prognostic biomarker in colorectal cancer [1, 1]. Gene expression panels including SEMA3E can predict overall survival in stage-matched colorectal cancer patients. SEMA3E is also included in glutamine-related gene signatures that predict prognosis in colorectal cancer [<a href="#ref-1">1</a>].

**Pilocytic astrocytoma**: SEMA3E is overexpressed in pediatric pilocytic astrocytomas [<a href="#ref-1">1</a>]. The overexpression of SEMA3E, along with SEMA5A, suggests a role for semaphorin signaling in the pathogenesis of this brain tumor.

**Other cancers**: SEMA3E expression is altered in endometrial cancer [1, 1], renal cell carcinoma [<a href="#ref-1">1</a>], and melanoma [<a href="#ref-1">1</a>]. In these cancers, SEMA3E expression correlates with immune infiltration and response to immune checkpoint blockade therapy.

### 4.5 Inflammatory and Immune-Mediated Diseases

**Asthma**: SEMA3E is downregulated in the airways of severe asthmatics [<a href="#ref-1">1</a>]. The SEMA3E-PlexinD1 axis modulates regulatory T-cell function in a house dust mite model of asthma. PlexinD1 deficiency in CD11c+ dendritic cells exacerbates airway hyperresponsiveness, IgE production, and mucus production in allergic asthma [1, 1]. Similarly, PlexinD1 deficiency in lung interstitial macrophages exacerbates house dust mite-induced allergic asthma [<a href="#ref-1">1</a>].

**Atherosclerosis**: SEMA3E is expressed in atherosclerotic plaques and regulates macrophage retention [<a href="#ref-1">1</a>]. The expression of SEMA3E in plaques promotes the retention of myeloid-derived cells, contributing to the persistence of inflammation in advanced atherosclerotic lesions.

**Inflammatory bowel disease**: SEMA3E regulates apoptosis in the intestinal epithelium during the development of colitis [<a href="#ref-1">1</a>]. Sema3e-deficient mice show altered susceptibility to experimentally induced colitis, indicating a protective role for SEMA3E in intestinal homeostasis.

**Rheumatoid arthritis**: SEMA3E is among the semaphorins dysregulated in rheumatoid arthritis [<a href="#ref-1">1</a>]. The expression of class 3 semaphorins in synovial tissue contributes to the angiogenic and inflammatory processes that drive joint destruction.

### 4.6 Neurological and Neurodegenerative Disorders

**Epilepsy**: Plasma SEMA3E has been identified as a diagnostic biomarker for human epilepsy [<a href="#ref-1">1</a>]. Integrated bioinformatics analysis of transcriptomic data from brain tissue and blood of epilepsy patients identified SEMA3E as a common differentially expressed gene. The diagnostic potential of plasma SEMA3E levels warrants further investigation.

**Alzheimer's disease**: SEMA3E expression is altered in Alzheimer's disease, as revealed by spatial transcriptomics studies [1, 1]. The expression pattern of SEMA3E shifts in the middle temporal gyrus and entorhinal cortex with advancing Braak stage, suggesting a role in neurodegeneration.

**Ischemic stroke**: SEMA3E is among the chemokine-related genes deregulated in ischemic stroke [<a href="#ref-1">1</a>]. The expression of SEMA3E correlates with immune infiltration in the ischemic brain, suggesting a role in the neuroinflammatory response to stroke.

### 4.7 Other Clinical Associations

**Obesity**: Heterozygous variants of SEMA3E have been identified in patients with morbid obesity [1, 1]. The association between SEMA3E variants and obesity is consistent with the role of SEMA3E in beige adipocyte differentiation and thermogenesis [<a href="#ref-1">1</a>].

**Fuchs endothelial corneal dystrophy**: SEMA3E is among the genes differentially expressed in Fuchs endothelial corneal dystrophy with and without trinucleotide repeat expansion in TCF4 [<a href="#ref-1">1</a>].

**Intervertebral disc degeneration**: Single-cell sequencing has revealed SEMA3E expression in nucleus pulposus cells, with altered expression during intervertebral disc degeneration [<a href="#ref-1">1</a>].

**Quail egg quality**: Polymorphisms in SEMA3E are associated with egg quality traits in Japanese quail [1, 1]. This non-human application demonstrates the conservation of SEMA3E function across species.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

The role of SEMA3E in host-pathogen interactions is an emerging area of research. While direct interactions between viral proteins and SEMA3E have not been extensively characterized, several lines of evidence suggest that SEMA3E signaling may be modulated during viral infections:

**SARS-CoV-2 and ACE2**: The SEMA3E receptor Plexin-D1 is expressed on endothelial cells, which are primary targets of SARS-CoV-2 infection. Viral infection of endothelial cells leads to dysregulation of SEMA3E-PlexinD1 signaling, potentially contributing to the vascular pathology observed in severe COVID-19. However, direct evidence for SEMA3E involvement in COVID-19 pathogenesis is currently lacking.

**Oncogenic viruses**: The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) has been shown to modulate semaphorin signaling in infected B cells. While the specific effects on SEMA3E have not been characterized, the dysregulation of semaphorin pathways by oncogenic viruses may contribute to virus-associated malignancies.

### 5.2 Bacterial Interactions

**Helicobacter pylori**: Infection with H. pylori, a bacterial pathogen associated with gastric cancer, leads to alterations in host gene expression, including genes involved in cell migration and adhesion. While SEMA3E has not been directly implicated in H. pylori pathogenesis, the effects of the bacterium on epithelial cell migration may involve semaphorin signaling.

**Gut microbiota**: The gut microbiota modulates host gene expression, including genes involved in axon guidance signaling [<a href="#ref-1">1</a>]. While the specific effects on SEMA3E have not been characterized, the modulation of semaphorin signaling by the microbiota may contribute to the effects of the microbiome on brain development and function.

### 5.3 Immune Evasion Mechanisms

The SEMA3E-PlexinD1 axis plays a role in immune regulation, and pathogens may exploit this pathway for immune evasion:

**Macrophage polarization**: SEMA3E regulates macrophage phenotype and function in response to LPS [<a href="#ref-1">1</a>]. Pathogens that modulate SEMA3E expression or signaling may be able to skew macrophage polarization toward a more permissive phenotype, facilitating infection.

**Regulatory T cells**: The SEMA3E-PlexinD1 axis modulates Foxp3+ regulatory T-cell function [<a href="#ref-1">1</a>]. Pathogens that disrupt this axis may be able to suppress regulatory T-cell responses, leading to enhanced inflammation and tissue damage.

**Dendritic cell function**: PlexinD1 signaling in dendritic cells is critical for IL-10 production [<a href="#ref-1">1</a>]. Pathogens that interfere with SEMA3E-PlexinD1 signaling in dendritic cells may be able to suppress the anti-inflammatory response, promoting excessive inflammation.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of SEMA3E Signaling

The SEMA3E-PlexinD1 axis represents a potential therapeutic target for multiple diseases, including cancer, inflammatory disorders, and metabolic diseases. Several approaches are being explored:

**Monoclonal antibodies**: Antibodies targeting SEMA3E or Plexin-D1 have been developed for research purposes and are being evaluated for therapeutic potential. Anti-SEMA3E antibodies that block the interaction with Plexin-D1 could be used to inhibit SEMA3E signaling in cancers where it promotes tumor progression.

**Small-molecule inhibitors**: The GAP domain of Plexin-D1 represents a potential target for small-molecule inhibitors. Compounds that inhibit the GAP activity of Plexin-D1 would block SEMA3E signaling downstream of receptor activation. However, the development of such inhibitors is at an early stage.

**Peptide inhibitors**: Peptides derived from the SEMA3E Sema domain that compete with full-length SEMA3E for binding to Plexin-D1 could act as antagonists. Such peptides have been developed for other semaphorin family members and could be adapted for SEMA3E.

### 6.2 Natural Compounds Modulating SEMA3E Expression

Several natural compounds have been shown to modulate SEMA3E expression:

**Flavonoids**: The combination of naringenin, hesperetin, curcumin, polydatin, and quercetin synergistically decreases SEMA3E expression levels in in vitro models of insulin resistance [<a href="#ref-1">1</a>]. This finding suggests that dietary flavonoids could be used to modulate SEMA3E expression in metabolic diseases.

**Fisetin**: The natural flavonoid fisetin inhibits cellular proliferation of hepatic, colorectal, and pancreatic cancer cells through modulation of multiple signaling pathways [<a href="#ref-1">1</a>]. While the specific effects on SEMA3E have not been characterized, the anti-cancer effects of fisetin may involve modulation of semaphorin signaling.

**Vitamin D**: 1,25-dihydroxyvitamin D3 transcriptionally regulates class 3 semaphorins in osteoblasts [<a href="#ref-1">1</a>]. Vitamin D analogs could be used to modulate SEMA3E expression in bone diseases.

### 6.3 Gene Therapy Approaches

**AAV-mediated gene delivery**: Adeno-associated virus (AAV) vectors could be used to deliver SEMA3E to tissues where it is deficient. This approach could be applied to diseases caused by SEMA3E haploinsufficiency, such as CHARGE syndrome and Kallmann syndrome.

**CRISPR-based approaches**: CRISPR-Cas9 gene editing could be used to correct pathogenic SEMA3E mutations. This approach is technically challenging but could provide a permanent cure for monogenic disorders caused by SEMA3E mutations.

**RNA-based therapies**: Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) could be used to knockdown SEMA3E expression in cancers where it promotes tumor progression. Alternatively, splice-switching oligonucleotides could be used to modulate alternative splicing of SEMA3E.

### 6.4 Pharmacogenomic Considerations

The association between SEMA3E variants and drug response is an emerging area of pharmacogenomics. Genetic variants in SEMA3E may influence the response to:

**Anti-angiogenic therapies**: SEMA3E is an anti-angiogenic factor, and its expression may influence the response to VEGF-targeted therapies. Patients with high SEMA3E expression may respond differently to anti-angiogenic drugs.

**Immune checkpoint inhibitors**: SEMA3E expression correlates with immune infiltration in several cancer types [1, 1]. SEMA3E expression levels may serve as a biomarker for response to immune checkpoint blockade therapy.

**Metabolic drugs**: The role of SEMA3E in beige adipocyte differentiation and thermogenesis suggests that SEMA3E could be a target for drugs aimed at treating obesity and metabolic syndrome.

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|---|---|---|
| HGNC | 10723 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10723 |
| NCBI Gene | 9723 | https://www.ncbi.nlm.nih.gov/gene/9723 |
| Ensembl | ENSG00000170381 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000170381 |
| UniProt | O15041 | https://www.uniprot.org/uniprotkb/O15041/entry |
| RCSB PDB | (Structural models via homology) | https://www.rcsb.org/ |
| OMIM | 608166 | https://www.omim.org/entry/608166 |
| ClinVar | SEMA3E | https://www.ncbi.nlm.nih.gov/clinvar/?term=SEMA3E |
| GTEx | SEMA3E | https://gtexportal.org/home/gene/SEMA3E |
| STRING | 9606.ENSP00000355355 | https://string-db.org/ |
| BioGRID | 120512 | https://thebiogrid.org/ |
| GeneCards | GC07M083895 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SEMA3E |
| Human Protein Atlas | ENSG00000170381 | https://www.proteinatlas.org/ENSG00000170381-SEMA3E |
| COSMIC | SEMA3E | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SEMA3E |
| CCLE | SEMA3E | https://portals.broadinstitute.org/ccle |

### Gene Ontology (GO) Terms

| Category | GO Term | Description |
|---|---|---|
| Molecular Function | GO:0030215 | Semaphorin receptor binding |
| Molecular Function | GO:0005515 | Protein binding |
| Biological Process | GO:0007411 | Axon guidance |
| Biological Process | GO:0001525 | Angiogenesis |
| Biological Process | GO:0048846 | Axon extension involved in axon guidance |
| Biological Process | GO:0030335 | Positive regulation of cell migration |
| Biological Process | GO:0048666 | Neuron development |
| Biological Process | GO:0007165 | Signal transduction |
| Cellular Component | GO:0005576 | Extracellular region |
| Cellular Component | GO:0005615 | Extracellular space |

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] "SEMA3E Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/2b04081dac5771f914075a4a761